@FierceMedDev: Special Report: 2013's top FDA approvals in med tech. Report | Follow @FierceMedDev
@MarkHFierce: Check out the latest issue of FierceDiagnostics, now with expanded biomarker coverage. Issue | Follow @MarkHFierce
@MichaelGFierce: NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Covidien gets FDA OK for LigaSure laparoscopic surgical device. News | Follow @EmilyWFierce
> California's Medina Medical said it raised $7.7 million in a Series B preferred financing round to propel development of its embolization devices to treat neurovascular disease. Item
> Case Western Reserve University and University Hospitals Case Medical Center are developing a better imaging method to help assess stents placed in coronary arteries. The NIH is fueling the effort with a $1.7 million grant. Item
> The Bay State's Codman Neuro disclosed that the FDA has assigned Class I recall status to its Trufill n-BCA liquid embolic system--the agency's most serious. Codman issued a global medical device correction notice after reports that the mix could solidify too slowly and harm patients. Item
> EndoChoice won Canadian regulatory approval to start marketing its Fuse endoscopy system. Item
> Toronto's Amorfix Life Sciences has inked a deal with "a major global pharmaceutical copany" to use its Alzheimer's disease diagnostic assay in a clinical trial that will test a novel Alzheimer's treatment. Item
Biotech News
@FierceBiotech: The dethroned 'King of Biotech' will stay exiled in prison. News | Follow @FierceBiotech
@JohnCFierce: The 4th quarter was big--Q4 venture haul pushes 2013 biotech investing past $4.5B--and the year was fine, overall. Story | Follow @JohnCFierce
@DamianFierce: Your chance to vote: Who are the most influential people in biopharma today? Survey | Follow @DamianFierce
@EmilyMFierce: ICYMI, yesterday's edition of FierceBiotech Research featured Alzheimer's research and new nanotech. Read | Follow @EmilyMFierce
> Boehringer, Zealand hit reset on GLP-1 diabetes program. More
> U.K. mulls a 'breakthrough' drug program of its own. Article
> Yale researchers chide the FDA for failing to enforce high R&D standards. Coverage
Pharma News
@FiercePharma: What's a $2.9B deal + increasing sales equal? One enthused new CEO at Forest. Yesterday's story | Follow @FiercePharma
@TracyStaton: Here's my story on yesterday's Swiss job shuffle. Story | Follow @TracyStaton
@EricPFierce: Who do you think are the most influential people in biopharma? Like to see someone from manufacturing. Survey | Follow @EricPFierce
@CarlyHFierce: Vivus has lost more than half its board, its CFO, 2 CEOs and 20 staffers--and now its commercial chief, apparently. More | Follow @CarlyHFierce
> Now it's New York: Novartis eyes another 500-plus job cuts with plant shutdown. News
> Appeals court gives GSK another shot at AbbVie in HIV drug-pricing fight. Story
> Sanofi's MS pill Aubagio wins final thumbs-up from U.K. cost-effectiveness watchdogs. More
> Par Pharma nabs injectables specialist JHP for $490M in private-equity auction. Report
Drug Delivery News
> Nano-scaffold delivers genetic treatment to spur blood vessel growth. News
> Biotronik launches drug-releasing balloon Passeo-18 Lux in Europe. Article
> NanoViricides snags a $20M offering to push virus-killing nanotech for flu, dengue through clinic. Story
> Rooted delivery vehicles use electric charge and gravity to release drugs over time. Piece
> Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story
> Novartis launches joint pain gel in India with Phosphagenics' delivery tech. Item
Diagnostics News
> Researchers from Singapore and China find a new esophageal cancer biomarker. More
> A finger-prick blood test could uncover sports concussions on the field. Article
> Myriad Genetics will market a breast cancer Dx made by a Siemens spinoff. Story
> FDA approves Affymetrix's blood test for developmental disabilities. Coverage
> Illumina brings next-generation sequencing to Amgen companion Dx deal. News
> LabCorp CEO promises continued rollout of new genomics-based Dx tests. Item